Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

18 Stocks Moving In Monday's Pre-Market Session

UVE, AAQL, ARRY, CRNT, GILT, REGN, TEVA

Gainers

  • Tahoe Resources Inc (NYSE: TAHO) rose 43 percent to $6.72 in pre-market trading after the company disclosed that the Guatemalan Supreme Court issued a decision that reinstates the Escobal mining license of its Guatemalan subsidiary.
  • Marinus Pharmaceuticals Inc (NASDAQ: MRNS) rose 28.2 percent to $4.00 in pre-market trading after the company issued trial results from its Phase 2 study of CDKL5.
  • Idera Pharmaceuticals Inc (NASDAQ: IDRA) rose 16.4 percent to $2.27 in pre-market trading after the company disclosed positive Phase 1 data for intratumoral IMO-2125 in combination with ipilimumab.
  • Universal Insurance Holdings, Inc. (NYSE: UVE) shares rose 11.8 percent to $19.95 in pre-market trading after gaining 8.51 percent on Friday.
  • Richmont Mines Inc. (USA) (NYSE: RIC) rose 11.5 percent to $10.65 in pre-market trading. Alamos Gold announced plans to acquire Richmont Mines. Richmont Mines also announced sale of Quebec assets to Monarques Gold.
  • Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) rose 11 percent to $17.20 in pre-market trading. Teva named Kåre Schultz as President and CEO. BTIG Research upgraded Teva from Neutral to Buy.
  • Blue Capital Reinsurance Holdings Ltd (NYSE: BCRH) rose 7.5 percent to $15.10 in pre-market trading after declining 6.64 percent on Friday.
  • Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) rose 7.3 percent to $6.06 in pre-market trading. Foresight disclosed that it has successfully completed pilot project with one of the China's top three largest car manufacturers.
  • Ceragon Networks Ltd (NASDAQ: CRNT) rose 7.2 percent to $2.24 in pre-market trading.
  • Array Biopharma Inc (NASDAQ: ARRY) rose 6.6 percent to $11.70 in pre-market trading as the company reported positive Phase 3 COLUMBUS part 2 results in BRAF-mutant melanoma.
  • Gilat Satellite Networks Ltd. (NASDAQ: GILT) shares rose 6.5 percent to $6.07 in pre-market trading. Globe Telecom has awarded Gilat a five year multi-million dollar contract for managed service satellite backhaul for cellular services.

Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

Losers

  • Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) shares fell 26.7 percent to $3.60 in pre-market trading. Janssen terminated worldwide collaboration for Hepatitis C With Achillion Pharmaceuticals. Achillion named Joseph Truitt as COO.
  • CGG SA (ADR) (NYSE: CGG) fell 6.3 percent to $5.65 in pre-market trading after dropping 2.58 percent on Friday.
  • Synergy Pharmaceuticals Inc (NASDAQ: SGYP) fell 6.1 percent to $2.62 in pre-market trading after declining 7.31 percent on Friday.
  • Verastem Inc (NASDAQ: VSTM) fell 5.1 percent to $5.02 after gaining 7.09 percent on Friday.
  • Pioneer Natural Resources (NYSE: PXD) fell 4.4 percent to $122.82 in pre-market trading after dropping 2.49 percent on Friday.
  • Israel Chemicals Ltd. (NYSE: ICL) fell 3.7 percent to $4.21 in pre-market trading following report Postash may sell stake in company ahead of merger with Agrium.
  • Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) shares fell 3 percent to $457.50 in pre-market trading. Regeneron and Sanofi announced positive dupilumab topline results from Phase 3 trial in uncontrolled persistent asthma.


Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today